AI
AKYA

Atom Investors’s Akoya BioSciences AKYA Stock Holding History

Atom Investors’s Portfolio AKYA Stock Details AKYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-47,087
Closed -$65.5K – 596
2025
Q1 		$65.5K Buy
+47,087
New +$103K 0.01% 457

Other funds holding AKYA

BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCA
Peddock Capital Advisors Braintree, Massachusetts $501M AUM 29.8% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Atom Investors's AKYA Position: Q2 2025 in Review

Atom Investors sold out of Akoya BioSciences (AKYA) in Q2 2025, closing a stake of 47,087 shares — an estimated $65.5K sold.

Atom Investors first reported a position in AKYA in Q1 2025 and held it in 1 quarter. The position peaked at $65.5K in Q1 2025. 58 funds tracked by Wall St. Rank hold AKYA as of Q2 2025.

  • Atom Investors reported no remaining Akoya BioSciences position as of Q2 2025 after selling out during the quarter.
  • Atom Investors sold 47,087 Akoya BioSciences shares in Q2 2025, an estimated $65.5K.
  • Atom Investors first reported a position in Akoya BioSciences in Q1 2025 and held it in 1 quarter.
  • Atom Investors's Akoya BioSciences position peaked at $65.5K in Q1 2025.
  • 58 funds tracked by Wall St. Rank held Akoya BioSciences as of Q2 2025.

Based on Atom Investors's 13F filing for Q2 2025, filed 14 Aug 2025.